14
Oct

GW Pharmaceuticals’ in-development treatment for ulcerative colitis missed its primary endpoint in a midstage trial, a setback for the U.K. drugmaker and its pipeline of cannabinoid treatments.

…read more

Source: GW Pharma’s cannabis-based drug comes up short in ulcerative colitis

    

0 No comments